| Size | Price | Stock |
|---|---|---|
| 5mg | $60 | In-stock |
| 10mg | $72 | In-stock |
| 25mg | $144 | In-stock |
| 50mg | $216 | In-stock |
| 100mg | $336 | In-stock |
| 200mg | $600 | In-stock |
| 500mg | $1000 | In-stock |
| 1g | $1400 | In-stock |
| 5 g | Get quote | |
| 10 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15147 |
| M.Wt: | 312.31 |
| Formula: | C14H11F3N2OS |
| Purity: | >98 % |
| Solubility: | DMSO : 15.62 mg/mL (ultrasonic;warming;heat to 60°C) |
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation[1][2][3].
IC50 & Target:IC50: 5 nM (TNKS1), 2 nM (TNKS2)[1]
In Vitro: XAV-939 has activity against TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively[1].
XAV-939 (0.3-30 μM; 3 or 10 days) enhances osteoblast differentiation of hBMSCs[2].
XAV-939 (3 μM) promotes osteoblast differentiation of hMSCs via accumulation of SH3BP2[2].
XAV-939 (3 μM; 10 days) upregulates the expression of OPG and downregulates the expression of RANKL in hBMSCs during osteoblast differentiation[2].
XAV-939 suppresses Wnt/β-catenin signaling and promotes SFRP3 and SFRP4 expression[3].
In Vivo: XAV-939 rescues mechanical stress-induced cartilage degeneration in vivo[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.